CATHERINE MCNAMARA: Open Payments
NPI 1649364613 · RENO, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$956 in 40 payments from 14 companies in 2025. Trend: 2023 $1,066 · 2024 $972 · 2025 $956
Food & beverage: $956
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $156 |
| ABBVIE INC. | 6 | $130 |
| PFIZER INC. | 5 | $126 |
| Astellas Pharma US Inc | 3 | $101 |
| Novo Nordisk Inc | 4 | $96 |
| Lilly USA, LLC | 4 | $86 |
| Amgen Inc. | 3 | $74 |
| Sumitomo Pharma America, Inc. | 2 | $50 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| Corcept Therapeutics | 1 | $28 |
Products named: Veozah, NURTEC ODT, VRAYLAR, MOUNJARO, FARXIGA, BREZTRI, Ozempic, GEMTESA.
Industry payments across NV — which companies pay providers there.
